Market Update

ASX Pre-Market: Tuesday, 8 September 2026
Market Update

ASX Pre-Market: Tuesday, 8 September 2026

ASX SPI 200 futures point to a flat, slightly lower open as oil, gasoline and copper push to fresh highs after a weekend Iran escalation. Ahead of today's session: NAB Business Confidence, and bank exposure to the $3.4 billion Bathla Group collapse.

When the Crowd Becomes the Analyst: Inside the Rise of Prediction Markets
Finance

When the Crowd Becomes the Analyst: Inside the Rise of Prediction Markets

A contract trading at sixty-seven cents means thousands of strangers just told you, with real money, what they think the odds actually are. That's the whole idea behind prediction markets, and in the eighteen months since the 2024 election, it's gone from a curiosity to a $30-billion-a-month industry. Here's how a decades-old academic experiment became one of the fastest-growing instruments in finance.

The Wall Street Wrap: September 4, 2026
Market Update

The Wall Street Wrap: September 4, 2026

US stocks closed lower Friday as a blowout August jobs report revived Fed rate-hike bets, undoing Thursday's rally. Nvidia's growing equity-investment stake, Amgen's FTC antitrust overhang, and a strong week for chip and memory names rounded out a busy session ahead of next week's make-or-break CPI print.

Global Food Prices Are Rising Everywhere at Once. Here Is Why
Global Economy

Global Food Prices Are Rising Everywhere at Once. Here Is Why

Global food prices surged in August to their highest level since 2022 as every major FAO commodity index rose together, with sugar leading a broad-based move driven by European weather damage, El Nino risk, Black Sea disruption and India's sugar import policy.

The Wall Street Wrap: September 3, 2026
All Sectors

The Wall Street Wrap: September 3, 2026

Stocks post best day since August as Fed's Waller signals rates may hold steady. US stocks rallied to their best session in a month after Fed Governor Christopher Waller signaled openness to holding rates steady, sending yields lower and lifting risk assets broadly. But the day's earnings reports told a more mixed story: DocuSign and Smith & Wesson surged on strong beats, while Guidewire and Lululemon plunged after hours despite beating on key metrics, a reminder that guidance is driving reactions more than headline numbers this earnings season.

How a chatbot rewired America's power grid — and turned dull utility stocks into an AI trade
Artificial Intelligence (AI)

How a chatbot rewired America's power grid — and turned dull utility stocks into an AI trade

Data-centre electricity demand barely moved for a decade — then ChatGPT launched, and the grid never looked the same. We trace the numbers behind the shift, and the utility stocks now riding America's biggest electricity re-rating in a generation.

AI Stock Bubble 2026: Inside the $700 Billion Bet Wall Street Can't Verify
Artificial Intelligence (AI)

AI Stock Bubble 2026: Inside the $700 Billion Bet Wall Street Can't Verify

Concentration in Big Tech has hit records not seen since the dot-com era, and the payoff that is supposed to justify it has yet to show up

Wall Street Wrap: September 2, 2026
All Sectors

Wall Street Wrap: September 2, 2026

Wall Street rebounded on Wednesday, breaking a three-day losing streak as the recent spike in Treasury yields eased off. The Dow led the charge, helped by gains in Nvidia and Johnson & Johnson, while the S&P 500 and Nasdaq 100 also closed firmly in the green. The VIX dropped nearly 7%, signaling a notable cooldown in hedging demand after a jittery start to the week. Breadth was healthy across the board, with the bulk of S&P sectors finishing higher on the day.

From Radiant World to First Brands: A Pattern in Private Credit Risk
Finance

From Radiant World to First Brands: A Pattern in Private Credit Risk

A fresh investigation into commodity trader Radiant World, alongside the earlier First Brands Group collapse, shows how collateral verification gaps can trigger credit rationing and liquidity risk in US private credit.

FDA Calendar September 2026: PDUFA Dates, First-in-Class Drugs & Biotech Stocks to Watch
Healthcare Stocks

FDA Calendar September 2026: PDUFA Dates, First-in-Class Drugs & Biotech Stocks to Watch

September could be a decisive month for biotech investors. The FDA faces a crowded calendar of PDUFA decisions, first-in-class therapies and a landmark advisory-panel review. From gene therapy and rare diseases to oncology and diagnostics, the outcomes could reshape valuations across a group of closely watched biotech stocks.